We recently published a list of 10 Best Immunology Stocks To Buy Now. In this article, we are going to take a look at where ...

This decision suggests that Winrevair has shown significant benefits ... HYPERION trial early could serve as a strong catalyst for Merck’s stock, especially if the efficacy endpoint is met ...

Merck shares have been under pressure amid disappointing sales trends for its Gardasil HPV vaccine. The company's broader ...

Merck's Q4 2024 results surpassed expectations, driven by strong oncology sales and growth in Keytruda. See why I think MRK ...

Management expects mid-to-high single-digit growth in Merck's total business outside of GARDASIL China in 2025, supported by increasing momentum in new product launches such as WINREVAIR and ...

Adding Winrevair to standard pulmonary arterial hypertension (PAH) treatment is generally safe and effective, a pooled trial ...

Merck & Co Inc (NYSE:MRK) achieved strong growth in 2024, driven by demand for its innovative portfolio, including KEYTRUDA and the successful launch of WINREVAIR. The company reached nearly 0.5 ...

Merck’s new drugs – Winrevair and Capvaxive – have been gaining momentum. On the flip side, Gardasil sales fell 17% to $1.55 billion, due to a continued decline in China. Januvia and Janumet ...

In the third quarter, Merck reported a decline of 11% in Gardasil sales to $2.31 billion. The newly approved Winrevair (sotatercept) for adults with pulmonary arterial hypertension generated sales ...

Merck MRK stock has declined 7.8% in the past month — in roughly the span after it announced fourth-quarter 2024 results and ...